Integra LifeSciences Holdings Corporation(IART)Earnings, Financials & Key RatiosIntegra LifeSciences Holdings Corporation (IART) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to maintain consistent profitability, highlighted by a massive $484.1 million net loss in 2025Q2, suggests that the risks associated with manufacturing remediation currently outweigh potential upside.
Integra LifeSciences Holdings Corporation (IART) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Integra LifeSciences Holdings Corporation (IART) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.54vs $0.41+31.7% | $392Mvs $382M+2.6% |
| Q1 2026 | Feb 26, 2026 | $0.83vs $0.79+5.1% | $435Mvs $430M+1.2% |
| Q4 2025 | Oct 30, 2025 | $0.54vs $0.43+25.6% | $402Mvs $430M-6.4% |
| Q3 2025 | Jul 31, 2025 | $0.45vs $0.43+4.7% | $416Mvs $414M+0.3% |
Recent stock market news and headlines for Integra LifeSciences Holdings Corporation (IART)
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Kirlew will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution. Kirlew will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution.
On June 30, 2026, Integra Lifesciences Holdings Corp (IART) shares fell 4.2% to $17.98, amid a 52-week trading range of $8.70 to $18.92. This decline comes desp
MITT, SVM and IART stand out as broker rating upgrades, earnings growth forecasts and screen criteria point to potential upside.
PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (Nasdaq: IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization.
Key metrics vs top competitors for Integra LifeSciences Holdings Corporation (IART)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.18 | $1.41B | -2.70 | 1.53% | -31.58% | -39.9% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $32.39 | $1.64B | -134.96 | 14.88% | -0.83% | -0.95% | — | |
| $283.80 | $40.64B | -186.71 | 35.9% | -9.05% | -15.13% | — | |
| $71.45 | $4.26B | 33.54 | 11.66% | 9.03% | 8.95% | — |
Integra LifeSciences Holdings Corporation (IART) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Integra LifeSciences Holdings Corporation (IART) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
May 5, 2026·SEC
Apr 15, 2026·SEC
Get notified when IART posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Integra LifeSciences Holdings Corporation (IART) stock FAQ — growth, dividends, profitability & financials explained
Integra LifeSciences Holdings Corporation (IART) reported $1.64B in revenue for fiscal year 2025. This represents a 12454% increase from $13.1M in 1996.
Integra LifeSciences Holdings Corporation (IART) grew revenue by 1.5% over the past year. Growth has been modest.
Integra LifeSciences Holdings Corporation (IART) reported a net loss of $495.8M for fiscal year 2025.
Integra LifeSciences Holdings Corporation (IART) has a return on equity (ROE) of -39.9%. Negative ROE indicates the company is unprofitable.
Integra LifeSciences Holdings Corporation (IART) had negative free cash flow of $10.1M in fiscal year 2025, likely due to heavy capital investments.
